Keji Pharmaceutical-B (02171) fell sharply by more than 16%. As of press release, it fell 16.78% to HK$4.77, with a turnover of HK$4.3 million.
The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) fell sharply by more than 16%, down 16.78% at press time, to HK$4.77, with a turnover of HK$4.3 million.
In terms of performance, the company's results for the year ended December 31, 2023. The group achieved R&D expenses of 662 million yuan (RMB, same below) during the period, a year-on-year decrease of 2.74%; loss attributable to shareholders of 748 million yuan, a year-on-year narrowing of 16.19%; and a basic loss of 1.34 yuan per share. The announcement stated that the main reason for the narrowing was the reduction in share-based remuneration.
Earlier, the company issued an announcement, and the company's board of directors announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received for an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. According to reports, CT041 is a potential first-of-its-kind autologous CAR-T cell candidate product targeting Claudin18.2 protein. It is used to treat Claudin18.2 positive solid tumors, mainly gastric cancer/esophagogastric junction adenocarcinoma and pancreatic cancer.